The Company’s subsidiary, Medicure International, Inc., has a supply contract for raw materials (active pharmaceutical ingredient) used in the manufacture of AGGRASTAT ® with a contract manufacturer …
The Company’s subsidiary, Medicure Pharma, Inc., has entered into a supply arrangement with a third-party manufacturer of ZYPITAMAG ® which will expire on September 19, 2029.
o the Company and its business can be found in the “Risk Factors” section of this Annual Report. 3 Table of Contents PART I ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS A. Directors …
Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: o the Company and its business can be found in the “Risk Factors” section of this Annual Report. 3 Table of Contents …
be attributed to a decrease in utilization of the product through insurance formularies, specifically Medicare Part D. Company’s retail pharmacy operating segment, Marley Drug, Gateway Pharmacy and W…
ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or c…
Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which…
Medicure Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MCUJF-DEBT
Debt stack $648,047
90%
Market cache reports total debt of $648,047.
Medicure Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Medicure Inc..
Medicure Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Medicure Inc..
